QualityStocks News Alert
  The QualityStocks Daily Newsletter for Tuesday June 16th, 2009 Blog  |  Video  |  Market Basics  |  Quotes & News  |  Clients  |  Partners  |  About Us  |  Contact Us

Today's Top 3 Investment Newsletters




Hot Shot Stocks (EDWY)


OTC Picks (BCND)

The QualityStocks Daily

Enhance Skin Products Inc. (EHSK)

Yesterday, Monster Stock Alerts and Mr. Liquid reported on Enhance Skin Products Inc. (EHSK), and today we highlight the Company as "One to Watch", here at the QualityStocks Daily Newsletter.

Enhance Skin Products, Inc. develops and sells cosmeceutical products. Trading on the OTCBB, the Company has their headquarters in Toronto, Ontario and offices in Denver, Colorado. They are part of the Personal Products industry in the Consumer Goods sector. Founded in 1992, Enhance Skin Products Inc. sells their products under the Visible Youth™ trademark.

Enhance Skin Products Inc. develops and distributes the Visible Youth™ Brand to physicians and skin therapy professionals. Their scientists’ base their twenty years of personal experience in research and development of medical and skincare on the use of hyaluronic acid (HA) for deep hydration. The Company’s professional skin care products contain the optimal size, purest and most effective HA molecule available to rehydrate skin at the cellular level. Their scientists developed Visible Youth to target the skin’s continuing need for sodium hyaluronate (HA).

The Company's products include Visible Youth Healing Complex Plus 3% Lidocaine.  A physician applies this following non-ablative skin resurfacing procedures. The purest and most effective hyaluronic acid (HA) molecular fraction available combines with bioactive ceramic micro-particles. This is to provide deep hydration and to aid in healing.

The Company’s Visible Youth Healing Complex™ product delivers a restorative formula to treated skin. This is following skin-resurfacing procedures including fractional laser, laser, chemical peel, IPL, and microdermabrasion treatments. This product also provides antimicrobial and anti-inflammatory properties.

Enhance Skin Products Inc.’s Visible Youth Revitalizing Cleanser™ is a mild, non-soap, and non-alkaline gel. They formulated this product for all skin types to gently remove impurities without breaking the acid mantle of the skin. The Company’s Visible Youth Revitalizing Skin Formula™ is a gel formulated to hydrate skin on the face and neck.

Their Visible Youth Revitalizing Eye Zone Gel™ combines HA with collagen and the healing antioxidant properties of Vitamin E. This aids in reducing the appearance of fine lines, wrinkles, and puffiness. It also helps improve skin tone and texture around the eyes. In addition, their Visible Youth Revitalizing Moisturizer™ cream delivers hydrating nutrition to the skin on the face and neck.

We're keeping an eye on Enhance Skin Products Inc. (EHSK), and tracking them on our radar screens as "One to Watch" this week, here at the QualityStocks Daily Newsletter.

Today, Enhance Skin Products Inc. (EHSK) closed trading at $0.28 up $0.03 or 12.00 percent. Volume was 106,720.

Eastbridge Investment Group Corp. (EBIG)

Today we choose to highlight Eastbridge Investment Group Corp. (EBIG), here at the Quality Stocks Daily Newsletter.

EastBridge Investment Group Corp. focuses on high-growth companies in Asia, offering Initial Public Offering's, Joint Ventures, and Merchant Banking services. The Company targets industries in electronics, real estate, auto, metal, energy, environmental, bioscience, and food retail distribution. They are the first OTCBB listed company whose primary business is helping Asian companies become publicly traded companies in the United States. Headquartered in Arizona, the Company also maintains an office in Beijing, China.

Eastbridge's revenues come from earning fees and marketable stock equities in the client companies they take public, and from making cash income by operating joint business ventures with their foreign partners. They also earn fees by providing merchant banking services to their diverse clientele. Their clients are primarily in mainland China, Hong Kong, Macao, Taiwan, Australia, and Southeast Asia.

Eastbridge seeks after opportunities that create excellent value for their shareholders and their clients and they only have an interest in business opportunities where the decision process is simple, and the return is within one to two years. They look for companies that have a demonstrated steady income stream or are set to launch impactful commercial products that offer double digit growth in market share.

EastBridge Investment Group announced last fall that they signed an agreement to acquire controlling interest in Aoxing Corporation. Aoxing is a manufacturer of electrical cables in Jiangxi, China. In business for seven years, Aoxing makes copper alloy electrical cables for the domestic and international markets.

On February 2, 2009, EastBridge Investment Group announced that they reached agreements to acquire a controlling stake in three companies in China with EastBridge's preferred stock. Two companies are in the shipbuilding and pharmaceutical industries. The third company is a diversified holding company. Their net incomes range from one to two million dollars per year.

Yesterday, the Company announced that their client, JinKuiZi, received granting of a new patent in China for a phosphorus production method using microorganisms. The product, Bio-Phosphorus fertilizer, does not cause air or soil pollution. It qualifies for organic farming as well as regular farming. The Chinese agricultural department conducted several pilot tests of this project and has confirmed its efficacy. JinKuiZi is working on completing their audit. They plan to become a public company. EastBridge is a substantial shareholder in JinKuiZi.

Eastbridge Investment Group Corp. (EBIG) closed at $0.017 for no change. Volume was 138,324 for a 3-month average volume of 88,952.

U.S. Global Investors Inc. (GROW)

We are highlighting U.S. Global Investors Inc. (GROW) today, here at the QualityStocks Daily Newsletter.

U.S. Global Investors Inc. is a registered investment adviser and management firm servicing retail and institutional investors. Headquartered in San Antonio, Texas, the Company trades on the NASDAQ, and provides advisory, transfer agency, and other services to U.S. Global Investors Funds, U.S. Global Accolade Funds, and other clients. U.S. Global Investors Inc. specializes in natural resources and emerging markets. Their corporate focus is on profitable niche markets around the world.

Founded in 1968 to manage a growth fund that evolved into their Gold Shares Fund, U.S. Global Investors Inc. has grown into a broad and diversified range of investments. They manage approximately $2.2 billion in mutual fund assets and have an established record of delivering self-directed investment solutions to a wide variety of companies, non-profit organizations, and pension plans.

U.S. Global Investors Inc. manages a family of 13 no-load mutual funds. These include all major asset classes and markets including gold and natural resources, stocks, government money markets, tax-free bonds, and emerging markets. The Company has many subsidiaries including United Shareholder Services, Inc., their transfer agent for mutual fund shareholders; U.S. Global Brokerage, Inc., their funds' distributor; and A&B Mailers, which provides mailing services.
On June 5, 2009, U.S. Global Investors, Inc. announced that they would continue their monthly dividend policy into the second half of 2009. Their board of directors voted to approve payment of a two-cents-per-share monthly dividend for all classes of common stock. This is for the third calendar quarter of 2009. The record date for the July dividend is end of business on July 13, and the payment date will be July 27. For August, the record date is August 10 and the payment date is August 24. For September, the record date is September 14 and the payment date is September 28.

U.S. Global Investors Inc. (GROW) closed today's trading session at $8.06 down $0.06 or 0.74 percent. Volume was 313,110, higher than the 3-month average of 129,995

Qualsec (QLSC)

Today we choose to report on Qualsec (QLSC), here at the QualityStocks Daily Newsletter.

Trading on the OTCBB, QualSec is the developer of the NanoNose, the next generation of electronic olfactory sensory technology. The Company develops proprietary detection systems, which meet the discrimination, sensitivity, and portability requirements of the homeland security market. Their systems are also for applications in other high volume markets. These include the health care, environmental, petrochemical, and food industries. Their technology also has near-term applications for protection against biological warfare agents and the spread of terrorist-initiated epidemics. Qualsec has their corporate headquarters in Chapel Hill, North Carolina.

The Company's NanoNose electronic nose can detect and quantify various airborne substances. The NanoNose is handheld and acts instantaneously, with their proprietary technology detecting a broad range of substances. This product can find use in detecting hazardous chemicals, biological weapons, explosives, and chemical agents. The calibration can be set to detect avian flu and other diseases that could reach pandemic levels.

The NanoNose is also highly effective for detecting explosives or illegal drugs. In Health and Medicine, it can help detect tuberculosis, diabetes, and numerous other illnesses in minutes by sampling the breath of patients. It can also check food products for contaminants such as E. coli. In addition, the NanoNose can detect toxic contaminants, exhaust impurities, bacterial fermentation, and other biological and chemical hazards. The technology can help locate and clean up contaminated sites.

Qualsec has their internally developed, proprietary ROder Technology. They implement this into powerful compact air samplers. Devices that operate on ROder Technology meet the needs of sensitivity and portability. They also provide real-time results accurately. A device that utilizes the ROder Technology will operate with four discrete functions. These are air circulation over the testing substrate, interaction of the testing compound with airborne chemicals, analysis of the test results, and communication of the results to the user.

Qualsec (QLSC) closed today's session at $0.40 up $0.28 or 233.33 percent. Volume was 500 shares for a 3-month average volume of 405 shares.

Symbollon Pharmaceuticals Inc. (SYMBA)

Today we highlight Symbollon Pharmaceuticals Inc. (SYMBA), here at the QualityStocks Daily Newsletter.

Headquartered in Framingham, Massachusetts, Symbollon Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on their I2 technology. Founded in 1986, Symbollon completed their initial public offering in December 1993. Trading on the OTCBB, they have pursued product applications for their technology in the areas of women’s healthcare and antimicrobial applications.

I2 is the chemical symbol for molecular iodine. Molecular iodine is the active species of iodine, a proven fast acting, broad-spectrum antimicrobial and therapeutic. In female health, Symbollon Pharmaceuticals Inc. developed a proprietary oral tablet based on their technology. It generates I2 "in situ" (the stomach of the patient). The Company calls this drug IoGen. IoGen is the first solid oral dosage form that delivers molecular iodine upon dissolution in gastric fluid. This approach to IoGen insures a stability profile for the drug.

IoGen is an oral dosage for the prevention and treatment of female health problems, including various types of premenopausal breast cancer, fibrocystic breast disease, and endometriosis. IoGen provides an oral dosage form for molecular iodine that is stable, tasteless, and well tolerated.

Symbollon Pharmaceuticals Inc. also develops IodoZyme.  It is an animal drug, and was the first product that incorporated "in situ" molecular iodine generation. IodoZyme is a powdered product that uses the enzyme horseradish peroxidase to form enzymatically molecular iodine upon dissolution in water. IodoZyme has found use in the United States by dairy farmers since 1995 and sells in the United Kingdom.

Symbollon has developed proprietary iodine technology that they believe maximizes the "therapeutic index" of iodine. The “therapeutic index” of a drug is the ratio of the largest safe dose to the smallest effective dose.  Symbollon Pharmaceuticals Inc.’s technology accomplishes this by controlling the ratio of molecular iodine, to the other inactive species of iodine normally present in a solution. Iodine has been shown to be a rapid acting, broad-spectrum antimicrobial. It has also shown to be an effective therapeutic for certain pharmaceutical applications. Symbollon Pharmaceuticals Inc. markets their pharmaceutical and healthcare products to hospitals, medical offices, dental offices, dialysis centers, outpatient clinics, and nursing homes.

Symbollon Pharmaceuticals Inc. (SYMBA) closed today at $0.02 up $0.01 or 81.82 percent. Volume was 15,000 shares.

Maxygen Inc. (MAXY)

Today we report on Maxygen Inc. (MAXY), here at the QualityStocks Daily Newsletter.

Founded in 1997, Maxygen Inc. focuses on the discovery, development, and marketing of protein pharmaceuticals for the treatment of disease and medical conditions. Their products are for the fight against cancer, hemostatis, and rheumatoid arthritis. The Company's headquarters are in Redwood City, California, and they trade on the NASDAQ. Their focus is on developing a series of technologies designed to improve specific properties of genes and proteins to create effective therapies to treat disease.

Maxygen has different protein pharmaceutical programs. MAXY-G34 is a granulocyte colony-stimulating factor (G-CSF) protein to treat neutropenia.  "Neutropenia" is a condition of an abnormally low number of a type of white blood cell called a neutrophil. The Company's MAXY-4 is an improved CTLA4-Ig protein to treat rheumatoid arthritis as well as other immune or autoimmune diseases. They partnered with Astellas Pharma, Inc., under which the Company and Astellas are exploring new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis, transplantation rejection, and other autoimmune disorders.

In 2008, Maxygen Inc. sold their hemophilia treatment program to Bayer's health care division for $90 million, in addition to $30 million in future milestone payments. Bayer acquired Maxygen's lead drug candidate MAXY-VII, along with a license to use their underlying gene targeting technology. MAXY-VII is an improved factor VIIa protein to treat hemophilia and acute bleeding conditions.

Last month, Maxygen, Inc. announced that they entered into an agreement with Cangene Corporation. They granted Cangene an option to obtain an exclusive license to Maxygen’s proprietary MAXY-G34 protein therapeutic for use in treating acute radiation syndrome (ARS). Under the agreement, Cangene has paid Maxygen an up-front fee of $500,000. If Cangene receives a specified government development contract that meets certain Cangene criteria, Cangene would exercise an option for an initial license and pay Maxygen an initial licensing fee.

Maxygen would also be entitled to additional licensing fees based upon a percentage of Cangene’s net contract revenues under the development contract. Maxygen Inc. retained all rights to MAXY-G34 for commercial development of all therapeutic areas outside of the ARS indication. This includes all rights for chemotherapy-induced neutropenia indications.

Maxygen Inc. (MAXY) closed today at $6.49 down $0.06 or 0.92 percent. Volume today was 149,258 for a 3-month average volume of 230,884 shares.

IncrediMail Ltd. (MAIL)

Greenbackers reported recently on IncrediMail Ltd. (MAIL) and we highlight the Company, here at the QualityStocks Daily Newsletter.

With headquarters in Tel-Aviv, Israel, IncrediMail is an Internet content and media company. Trading on NASDAQ, they are a part of the Business Software and Services industry. Founded in 1999, IncrediMail designs, markets and delivers high-end personal desktop software. Yaron and Ofer Adler founded IncrediMail. The Company began as Verticon, Ltd. and changed their name to IncrediMail, Ltd. in 2000. The Company went public in January 2006.

The Company believes the highlight of their products is the way they bring a new level of fun, personality, and convenience to email, desktops, and screen savers. Their award winning e-mail client product, IncrediMail Premium, sells in over 100 countries in 10 different languages. IncrediMail offers a unique solution for desktop wallpapers and screensavers with their product: Magentic. The Company also offers their HiYo product, which is a graphic add-on to instant messaging software.

In addition, another example of their product offering is their Gold Gallery. A content product, it offers additional content files in the form of email backgrounds, animations, sounds, graphics, and email notifiers. They also have their JunkFilter Plus, an advanced anti-spam product that offers a filtering technique to manage unwanted email, including offensive content, viruses, hoax emails, and identity theft scams.

IncrediMail Ltd. earns revenues by marketing premium software products, offering subscriptions to their content database, as well as licensing, and co-branding the Incredi brand to operators of third-party websites. They also earn revenues by selling paid advertising, sponsored links, and keyword search capabilities on IncrediMail’s website and email client. In July 2008, IncrediMail signed a contract with Google, making them a partner in Google's Ad Sense for Search program.

Last Thursday, IncrediMail Ltd. announced that they completed all the necessary requirements to become a certified McAfee SECURE™ website. The services will also include the Company’s Web site IncrediMail.com, as well their Magentic.com, PhotoJoy.com, and HiYo.com sites.

Today, IncrediMail Ltd. (MAIL) closed at $4.80 up $0.05 or 0.95 percent. Volume today was 15,006 for a 3-month average volume of 13,445.

Genta Incorporated (GNTA)

Standout Stocks, OTC Picks, Penny Performers, Penny Invest, Stock Egg, Cool Penny Stocks, Penny Stock Finder, and Today's Financial News reported recently on Genta Incorporated (GNTA), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Headquartered in Berkeley Heights, New Jersey, Genta Incorporated is a biopharmaceutical company in the biotechnology industry. They have a diversified product portfolio that focuses on delivering new products for the treatment of cancer patients. Founded in 1988, Genta Incorporated trades on the OTCBB.

Genta has two major research programs. These are DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from their DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma.
The leading drug in their Small Molecule program is Ganite® (gallium nitrate injection). Genta is exclusively marketing this drug in the United States for treatment of patients with cancer related hypercalcemia, which is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, which is a potential treatment for diseases associated with accelerated bone loss. This is currently in clinical trials. Genta is also developing tesetaxel, an oral semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel.

In December 2008, Genta Incorporated announced that they received notice from the U.S. Food and Drug Administration (FDA) that tesetaxel, received designation as an "Orphan Drug" for treatment of patients with advanced melanoma. Orphan drug status allows for a period of marketing exclusivity, certain tax benefits, and an exemption from certain fees upon submission of a New Drug Application.

Tesetaxel is a late Phase 2 oncology product. It has demonstrated anticancer activity in its initial clinical trials, and has not been associated with severe infusion reactions linked with other taxanes. Nerve damage has not been a prominent side effect of tesetaxel as it can be with other oral taxanes. Tesetaxel offers opportunities to improve patient convenience, safety, and anticancer activity.
Earlier this year, Genta Incorporated announced they initiated a new clinical trial with tesetaxel. The new study is examining the clinical pharmacology of the drug over a narrow dosing range around the established Phase 2 dose.

On June 3, 2009, Genta Incorporated announced preliminary results that show a high objective response rate and potentially extended survival in an ongoing pilot study that incorporates Genasense® (oblimersen sodium) Injection, in a chemotherapy program for patients with advanced melanoma. The data was featured the first week of June in a presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.

Genta Incorporated (GNTA) closed today's session at $0.0099, down $0.0003 or 2.94 percent. Volume was 114,698,297 significantly higher than their 3-month average volume of 3,651,570

The QualityStocks Company Corner

Avalon Oil & Gas, Inc. (AOGN)
Axial Vector Energy Corp. (AXVC)

Consorteum Holdings, Inc. (CSRH)
Kraig Biocraft Labs (KBLB)

Avalon Oil & Gas, Inc. (AOGN)

The QualityStocks Daily Newsletter would like to spotlight Avalon Oil & Gas, Avalon Oil & Gas, Inc. (AOGN). Today Avalon Oil & Gas, Inc. closed trading at $0.0156, for no change. Their volume today was 213,500 for a 3-month average volume of 77,716.

Avalon Oil & Gas, Inc. (AOGN) announced that it views the recent price rally in oil as encouraging for the industry and for its near term acquisition plans.

Avalon Oil & Gas, Inc. (AOGN) is an independent domestic oil and natural gas producer focused on leveraging efficient reservoir maintenance and innovative technologies to generate stable cash flows and production. By acquiring a portfolio of oil and gas leases to generate asset growth, the company aims to deliver a sustainable rate of return for their shareholders. Avalon currently owns working interests in Texas, Arkansas, Louisiana, and Oklahoma.

Instead of engaging in exploration and drilling exploration wells, the company invests in underdeveloped properties with existing stable cash flows. This relatively low risk business strategy enables Avalon to realize almost immediate cash flows and allows management to concentrate on expanding production of the acquired oil and gas properties.

The company is also in the process of acquiring a portfolio of new technologies developed for the oil and gas industry. Avalon first evaluates the commercialization potential with regard to technology and market viability, and then if merited, proceeds to rapid prototype development and field testing. The technologies currently under review were developed at leading universities and research labs, including the University of Wyoming and the Lawrence Livermore National Laboratory.

Even during challenging times, the world depends on oil & gas exploration and production companies to deliver millions of barrels of oil every day. Increased demand from emerging countries such as China further escalates competition for this precious resource. With a solid management team and impressive portfolio of leasehold interests and joint ventures, Avalon is well positioned to generate substantial revenues in the short and long term future. Disclaimer

Avalon Oil & Gas Company Blog

Avalon Oil & Gas, Inc. News:

Global Operations to Serve as Advisor to AVEC

AVEC Sells First License to Produce Engines in Malaysia with Premier Group of Kuala Lumpur

PETRO AVEC to Present Oxidative Desulphurization and Heavy Oil Upgrade Technology to 'The World Global Refining Summit' in Houston, Texas

Axial Vector Energy Corporation (AXVC)

The QualityStocks Daily Newsletter would like to spotlight Axial Vector Energy Corp. (AXVC). Today, Axial Vector Energy Corp. closed trading at $0.23, which was up $0.01 or 4.55 percent. Their volume today was 85,622 shares. Their 3-month average volume is 165,861.

Axial Vector Energy Corporation (AXVC) announced today that Global Operations LLC has agreed to serve as advisor to Axial Vector. Global Operation LLC will provide strategic planning and financial access to investors.

Axial Vector Energy Corporation (AXVC) a publicly traded, development-stage company providing global energy solutions, develops multi-fuel engines and generators for use primarily in military and commercial applications.

Founded in 2002, with headquarters in Portland, Oregon, Axial Vector - through a joint venture agreement with Adaptive Propulsion Systems, LLC - develops and manufactures their engines and generators with an eye toward environmental responsibility and social benefit.

Axial Vector Energy Corporation owns, develops and licenses a technologically advanced suite of internal combustion engines and electric power generation modules. The company has also developed the world's only “coreless” no iron electric motors, which consume one half the electricity of conventional electric motors.

These cutting-edge technologies are focused on fulfilling global engine and energy needs by delivering greater fuel-efficiency, cost effectiveness, versatility, and environmental sensitivity than ever before in venues from the commercial to the industrial, including the vehicular and military sectors. Disclaimer

Axial Vector Energy Corporation Blog

Axial Vector Energy Corporation News:

Global Operations to Serve as Advisor to AVEC

AVEC Sells First License to Produce Engines in Malaysia with Premier Group of Kuala Lumpur

PETRO AVEC to Present Oxidative Desulphurization and Heavy Oil Upgrade Technology to 'The World Global Refining Summit' in Houston, Texas


Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH) Today, Consorteum Holdings, Inc. closed trading at $0.50.

Consorteum Holdings Inc. announced that its common stock is now trading on the over the counter bulletin board under the symbol CSRH. The news follows yesterday's announcement that the holding company acquired Consorteum Inc., a systems integrator within the financial services, payment and transaction processing industries.

Consorteum Holdings, Inc. is focused on providing financial services, electronic transaction processing and management services to financial institutions, healthcare, government, public and private sector companies. The company's services provide customized, innovative technology solutions that create, augment and enhance their clients' existing financial, payment and transactional processing systems.

The company offers clients a long-term strategic plan utilizing the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create exceptionally customized programs. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new revenues.

Consorteum's strategy is to capitalize on the global opportunities within the growing financial services, payment and transaction processing marketplace. The utilized business model generates revenues on every transaction touched, thus providing long-term, sustainable income. The company has strategically designed its business initiatives to create significant repetitive transactions on an ongoing basis. Additional company revenues are generated from consulting services, project minimums and management fees.

The company is jointly led by CEO Craig Fielding and President & COO Quent Rickerby. Mr. Fielding brings a wealth of expertise in the payments industry, in both local and international payment processing, along with HR-specific business management expertise, leadership, customer development and acquisition skills. Mr. Rickerby brings over two decades of business management, international and domestic sales experience, new company start-up, payment processing, project management, business development, negotiations, relationship management and strategic company direction.Disclaimer

Kraig Biocraft Laboratories, Inc. (KBLB)

The QualityStocks Daily Newsletter would like to spotlight Kraig Biocraft Laboratories, Inc. (KBLB) Today, Kraig Biocraft Laboratories, Inc. closed trading at $0.028, which was down $0.011 or 28.21 percent from yesterday's close. Their volume today was 7,936,573 shares significantly higher than their 3-month average volume of 1,152,510 shares.

Kraig Biocraft Laboratories, Inc. (KBLB) a biotechnology company, has their focus on developing high performance polymers and technical fibers. The company is utilizing their proprietary genetic engineering technology to develop and produce polymers and protein-based materials, including Spider silk, which may have numerous commercial and consumer applications.

Kraig Biocraft Laboratories, Inc. (KBLB) is working with university scientists and laboratories to create these new polymers that have potentially broad applications in the multi-billion dollar marketplace for high performance polymers. The company sponsors and collaborates on research projects within university genetic engineering laboratories as a means of utilizing the greatest minds in their field.

Spider Silk is one of the strongest fibers produced in nature. The spider's repelling silk is of particular commercial interest since it is both extremely strong and extremely flexible. Although exciting commercial opportunities exist for the natural polymer, there is no known way to produce the fibers in commercial quantity. KraigLabs, in cooperation with two leading universities, has acquired proprietary genetic engineering technology to unlock the mystery.

CEO Kim Thompson leads the company with formal education in the fields of economics and law. With interest in genetic engineering dating back to the 1970s, Mr. Thompson has invented a pending provisional patent application for a number of organic polymers. This patent application has been assigned to benefit Kraig Biocraft and is a central part of the company's efforts in bringing those inventions to the market. Disclaimer

Kraig Biocraft Laboratories, Inc. Blog

News for Kraig Biocraft Laboratories Inc.

SectorWatch.biz: Paving the Way for Spider Silk

The following is an investment opinion release issued by EmergingStockReport.com

The New Silk Road

Kraig Biocraft Laboratories, Inc. Issues Stock Dividend


Daily Video
Get the latest market news every weekday at 11am EST with QualityStocks.net anchors Cathy Rankin, Vanessa Ramirez and Jenn Hoffman.

Sponsors of the Day


The QualityStocks Public Company Sponsor News


QualityStocks By The Numbers Report




About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

Home | Blog | Video | Market Basics | Media | Partners | Clients | About Us | Contact Us | Disclaimer | Unsubscribe
Copyright 2006-2009 QualityStocks 3370 N. Hayden Rd. Suite 123-591 Scottsdale, AZ 85251 480-308-0703